

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 33/00, 47/12		A1	(11) International Publication Number: WO 95/22335 (43) International Publication Date: 24 August 1995 (24.08.95)
(21) International Application Number: PCT/GB95/00338			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date: 17 February 1995 (17.02.95)			
(30) Priority Data: 9403284.4 21 February 1994 (21.02.94) GB 9404365.0 7 March 1994 (07.03.94) GB			
(71) Applicant (for all designated States except US): ABERDEEN UNIVERSITY [GB/GB]; Auris Business Centre, 23 St. Machar Drive, Aberdeen AB2 1RY (GB).			Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors; and (75) Inventors/Applicants (for US only): BENJAMIN, Nigel [GB/GB]; 20 The Chanony, Aberdeen AB2 1RQ (GB). DOUGALL, Hamish [GB/GB]; 10 Seafield Gardens, Aberdeen AB1 7YB (GB).			
(74) Agents: STEBBING, Peter, John, Hunter et al.; Ablett & Stebbing, 45 Lancaster Mews, Lancaster Gate, London W2 3QQ (GB).			

(54) Title: ACIDIFIED NITRITE AS AN ANTIMICROBIAL AGENT**(57) Abstract**

The invention relates to the use of acidified nitrite as an antimicrobial agent and describes a dosage form for use in the treatment of bacterial, viral or fungal conditions. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. Amongst the many potential applications for the invention, the inventive composition has been shown to be particularly effective as an animal feed supplement, and as an agent for sterilising objects. Compositions and methods of use for these applications are described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ACIDIFIED NITRITE AS AN ANTIMICROBIAL AGENT

The present invention relates to acidified nitrite as an antimicrobial agent.

5

Although nitrite has been used as a preservative for food for many years the mechanisms by which it kills microorganisms has not been elucidated. We have now found that nitrite in low concentration is effective in reducing the populations of 10 bacteria, fungi and viruses on the animal body when pH is below 4. We believe that this mechanism is used by mammals to destroy swallowed microorganisms.

An active entero-salivary circulation in man provides a 15 continuous flow of nitrate into the mouth where it is rapidly reduced to nitrite by bacteria on the tongue. The effect of salivary nitrate excretion is to provide a precursor for the generation of nitrogen oxides by the break down of the nitrite.

20

In brief we have found that exposure of a yeast, Candida albicans and the bacterium E. coli to concentrations of nitrite in saliva together with acid conditions similar to those found in the stomach for one hour caused a dose-dependent reduction 25 in their survival. It is apparent therefore that the generation of nitrogen oxides and/or nitrous acid in the mouth and in the gastrointestinal tract, particularly the upper gastrointestinal tract, from acidified nitrite is preventative of microbial infection.

30

In the mouth bacteria rapidly reduce nitrates to nitrites. Once swallowed the acid conditions of the stomach protonate the nitrite to form nitrous acid (pKa approx 3.5). The nitrous acid in turn dissociates to form oxides of nitrogen as shown 35 below.





Endogenous and dietary nitrate is actively concentrated by salivary glands to more than 10 times the concentration in plasma and secreted in saliva. Thus the saliva provides a continuous source of nitrate to the upper gastrointestinal tract. Oral conversion of nitrate to nitrite is rapid and is restricted to the surface of the tongue in man and to the posterior third of the tongue in the rat.

The function of the entero-salivary circulation of nitrate is not known but it may well be that gastric acid by itself is not always sufficient to destroy many ingested micro-organisms 15 and that the primary role of salivary nitrate secretion and conversion to nitrite is as a precursor for nitrogen oxides in the lumen of the stomach which will kill swallowed micro-organisms.

20 The above identified mechanism is also applicable to the destruction of micro-organisms on the skin. For example athlete's foot or tinea pedis.

25 We have found that nitrite at concentrations of up to 4% in
an inert carrier cream or ointment when mixed with an organic
acid such as salicylic acid reacts to produce oxides of
nitrogen which are effective in killing infectious organisms
on the skin including fungi, yeast, bacteria and viruses. The
combination of nitrite and acid causes mild erythema (redness)
30 of the skin due to release of nitric oxides but this causes
no significant inflammation.

The above identified mechanism is also useful in the sterilisation of objects such as dentures by utilising a sterilizing nitrate solution. Conventional solutions which are effective in sterilising dentures often taste unpleasant due to chlorine-based disinfectants. A combination of nitrite and

acid results in a antimicrobial solution which has little or no taste. Other objects such as contact lenses may be sterilised in the same way.

5 Gastroenteritis continues to be a major problem in rearing pigs and other farm animals. Enteropathogenic Escherichia coli (especially those bearing the K88 antigen) are particularly implicated. Although gastric acidity is thought to be one of the main host defence systems which provides a barrier to 10 orally-acquired infection, this is clearly ineffective in preventing organisms from reaching the more distal intestine in these animals.

According therefore to a first aspect of the present invention 15 there is provided a dosage form for the treatment of bacterial, virus, or fungal conditions which comprises:-

a pharmaceutically acceptable acidifying agent,
a pharmaceutically acceptable source of nitrite ions or
a nitrate precursor therefor, and
20 a pharmaceutically acceptable carrier or diluent, wherein
the acidifying agent is adapted to reduce the pH at the
environment of use to below pH4. Preferably the acidifying
agent is an organic acid, for example salicylic acid or
ascorbic acid. The precursor for the nitrite ion may be an
alkaline metal or alkaline earth metal nitrate capable of
25 conversion to a nitrate by enzymic action.

The pharmaceutical acceptable carrier or diluent may be an inert cream or ointment. In a particularly preferred form of 30 the invention the acidifying agent and the source of nitrite ions or precursor therefor are separately disposed in said cream or ointment for admixture to release nitrite ions at the environment of use.

35 Alternatively an acid composition may be presented for administration in tablet or liquid form.

In a further aspect of the invention there is provided a method of sterilising an object which method comprises the steps of

- 1) preparing a pharmaceutically acceptable acidifying agent and a pharmaceutically acceptable source of nitrite ions,
- 5 2) mixing said acidifying agent with said source of nitrite ions in a liquid carrier or diluent in contact with said object thereby to reduce the pH to below 4 while causing said sterilant nitrite ions to sterilize said object.
- 10

In a further form of the invention there is provided a sterilant composition comprising a pharmaceutically acceptable acidifying agent,

- 15 a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor,
- 20 and a pharmaceutically acceptable carrier or diluent therefor wherein the acidifying agent is adapted to reduce the pH at the environment of use to below pH4.

In a still further form of the invention there is provided an animal feed supplement comprising a pharmaceutically acceptable acidifying agent and,

- 25 a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, in an amount sufficient to produce a beneficial anti-bacterial pharmacological effect, but insufficient to produce adverse action in the target animal.

The acidifying agent may be salicylic or ascorbic acid as above, and the source of nitrite ions or nitrate precursor therefor may be in an inorganic nitrate as set forth above. Where the animal is the pig, the supplement should be included in an amount sufficient to ensure that each adult animal will receive a balanced dose of between 0.3 to 5.0 g/day and 35 preferably about 1 g/day.

The invention will now be described, by way of illustration

only, with reference to the following examples and figures accompanying the specification.

Figure 1 shows a diagram indicative of the effect of exposure 5 to nitrate and differing hydrogen ion concentrations on the survival of C albicans where the vertical axis is the optical density in absorbance units and the horizontal axis is the pH.

Figure 2 shows growth curves of E coli following exposure to 10 acid alone or acid with a nitrite where the vertical axes are optical density in absorbance units and the horizontal axes are time in hours.

Figure 3 shows growth curves of E coli following exposure to 15 pH3 in various nitrite concentrations where the vertical axis shows the optical density in absorbance units and the horizontal axis is time in hours.

Figure 4 shows the generation of nitric oxide from sodium 20 nitrite at different levels of acidity where the vertical axis is the nitric oxide concentration (nM) and the horizontal axis is Ph.

EXAMPLE 1

With reference to Figure 1 a single colony of C albicans was 25 used to inoculate an overnight culture in Sabouraud's broth. 10 μ l of this broth was added to 940 μ l of a citrate/phosphate buffered Sabouraud's broth to which was added sodium nitrite (50 μ l; final concentration 250 μ M) or distilled water as a 30 control. After one hour incubation at 37°C, 10 μ l was removed and cultured in 190 μ l standard Sabourauds broth with continual agitation (Gallenkamp orbital incubator) in a 96-well microtitre plate at 37°C. Growth was monitored by measurement 35 of optical density at 570nm at regular time intervals. The results are a mean of 16 separate experiments.

The effect of exposure to nitrite and differing hydrogen ion

concentrations on the survival of C albicans is shown in Figure 1. The open bars show the growth of C albicans measured by the optical density method following exposure to acid alone for 1 hour, while the closed bars show growth following 5 exposure to acid and 250 μ M sodium nitrite. There is a significant difference from the control at $p>0.05$ (Mann-Whitney U test). It is apparent therefore that the incubation of C albicans in acid alone for one hour had little effect on the number of viable organisms subsequently grown, whereas in 10 contrast the addition of sodium nitrite at 250 μ M incrementally killed C albicans as the pH was reduced to below 4. The nitrite was in fact effective in eliminating C albicans at pH 1 at all concentrations above 250 μ M (data not shown). 5nN nitrite killed C albicans at up to pH5. It is significant that 15 a random sample of 10 laboratory personnel on a normal diet had fasting salivary nitrite which varied from 23 to 220 μ M (mean 114 μ M) rising to 409 to 1890 μ M (mean 1030) 45 minutes after ingestion of 200mg potassium nitrate solution.

20 EXAMPLE 2

Figure 2 shows growth curves of E coli following exposure to acid alone (open symbols) or acid and 250 μ M nitrite (closed symbols). Growth was significantly ($p<0.05$) impaired at pH 2,3 and 4 in the presence of nitrite compared with control.

25 The same methods were used as in Figure 1 except E coli (strain NCTC 10418 grown on MacConkey's agar) was used and nutrient broth (Oxoid CM1) was used in place of Sabouraud's broth. The results shown in Figure 2 are a mean of 20 30 experiments. As can be seen from Figure 2 E coli is more susceptible to acid than C albicans. Nevertheless exposure to pH 2 for one hour does not kill all the organisms as there is significant growth in the nutrient broth. At pH3 many organisms survive. The addition of 250 μ M nitrite to the 35 exposure medium eliminates E coli at pH2 and significantly reduces the viability of this organism at pH3 and pH4. Nitrite at this concentration had no effect above pH4.

EXAMPLE 3

Figure 3 shows growth curves of E. coli following exposure to pH3 in various nitrite concentrations (10-1000 μ M final concentration). The methods are those as for Figure 2. Figure 5 3 shows that there is a direct relationship between the toxic effects of nitrite on E. coli and nitrate concentration at pH3. Even 10 μ M had a discernable effect whereas 1mM killed E. coli completely.

10 EXAMPLE 4

Figure 4 shows the generation of nitric oxide from sodium nitrite (as μ M) at different acidities. Conditions were the same as those used for the exposure of organisms in Figure 1. In particular nitrite was added to citrate/phosphate buffer 15 to achieve final concentrations shown in Figure 4. Nitric oxide concentrations in the buffer were measured by a nitric oxide sensitive meter (ISO-NO, World Precision Instruments) connected to a Maclab acquisition system and Macintosh computer. Measurements were recorded continually and readings 20 were taken at 2 minutes when nitric oxide concentration had reached a steady state. Figure 4 shows the release of nitric oxide as a result of reducing pH. Nitric oxide, which we have shown is generated under experimental conditions in Figure 4 readily diffuses through cell membranes and has a high 25 affinity for iron-sulphur containing respiratory enzymes and damages bacterial DNA. When produced enzymatically by activated leucocytes, nitric acid will kill Leishmania sp., Staphylococcus sp., Francisella sp. and Microbacterium as well as C. albicans. Reaction with superoxide under acid conditions 30 may additionally produce highly reactive hydroxyl radicals.

EXAMPLE 5

In a study to investigate the effect of a combination of salicylic acid at 2% w/w and sodium nitrite at 2% w/w in 9 35 patient volunteers with microbiologically proven fungal infection of the feet, application of the treatment produced a microbiological cure in all but one patient after 2 weeks

of therapy. The symptom score (derived from a scoring system which measures erythema, vesicles, pustules, desquamation, encrustation and pruritus) decreased from a mean of 7 before treatment to a mean of 2 following treatment.

5

EXAMPLE 6

10 Investigation of the use of nitrate or nitrite administered topically in the mouth in the form of toothpaste, mouthwash or other orally acceptable vehicle to reduce the number of caries-producing organisms in dental plaque and to treat to prevent infection with C albicans or other harmful organisms showed such application to be effective.

15 The observation that oxides of nitrogen produced non-enzymatically from nitrite under conditions simulating those in the stomach kills C albicans and E coli extends these observations to the intestinal tract. E coli is closely related to Salmonella, Shigella and other pathogenic 20 enterobacteria; all important causes of gastroenteritis in the mammal.

25 These results provide a rationale for active secretion of nitrate by the salivary glands. Nitrate itself is a innocuous precursor which only produces microbiocidal species when converted to nitrite and subjected to acid conditions. It is possible that Lactobacilli sp. transiently produce sufficient acid in the mouth after a carbohydrate meal to control the 30 growth of oral pathogens but clearly a moderate intake of nitrate may be a desirable prerequisite in any contaminated environment despite any potential as a precursor of nitrosamines.

35 Further the production of intestinal nitrogen oxides may be inadequate if the oral flora which convert nitrate to nitrite are suppressed following therapy with broad-spectrum antibiotics. Similarly if gastric acid production is reduced,

or if nitrate intake, which is largely dependent on leafy vegetables, is low this protective mechanism will be impaired. These are precisely the situations which predispose to oral and intestinal infections.

5

Whereas the foregoing study has concentrated on C albicans and E coli and the other organisms mentioned, it may also be important for providing protection from other serious gut pathogens which when swallowed may cause duodenal ulceration, 10 for example Helicobacter pylori, amoebic dysentery and chronic intestinal parasitism. Accordingly the invention provides a dosage form for the treatment of bacterial, viral or fungal conditions, a method of sterilising an object, and a composition therefor.

15

The above also suggests an inexpensive and simple means of prevention of gastroenteritis in farmed pigs by modification of dietary nitrate intake without the use of antibiotics.

CLAIMS

1. A dosage form for treatment of bacterial, viral or fungal conditions which comprises;
 - 5 a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, and a pharmaceutically acceptable carrier or diluent therefor, wherein the acidifying agent is present in an amount sufficient to reduce the pH at the environment of use to below pH4.
- 10 2. A dosage form according to claim 1 wherein the acidifying agent is an organic acid.
- 15 3. A dosage form according to claim 2 wherein the acidifying agent is salicylic or ascorbic acid.
- 20 4. A dosage form according to any preceding claim wherein the nitrate precursor is an alkali metal or alkali earth metal nitrate.
- 25 5. A dosage form according to any preceding claim wherein the pharmaceutically acceptable carrier is disposed in an inert cream or ointment, and wherein said acidifying agent and said source of nitrite ions is separately disposed in a respective cream or ointment for admixture to release nitrate ions at the intended environment of use.
- 30 6. A dosage form according to any of claims 1 to 4 in tablet or liquid form.
7. A method of sterilising an object which method comprises the steps of:-
 - 35 1) preparing a pharmaceutically acceptable acidifying agent and a pharmaceutically acceptable source of nitrate ions or a nitrate precursor therefor,

2) admixing said acidifying agent with said source of nitrite ions in a liquid carrier or diluent in contact with said object, thereby to reduce the pH to below 4 to release sterilant nitrite ions to sterilize said object.

5

8. A method according to claim 7 wherein said acidifying agent is an organic acid.

9. A method according to claim 8 wherein said organic acid
10 is a salicylic acid.

10. A method according to any of claims 7 to 9 wherein said precursor is an alkali metal or alkali earth metal nitrate.

15 11. A sterilant composition comprising a pharmaceutically acceptable acidifying agent,

a pharmaceutically acceptable form of nitrite ions or a precursor therefor,

20 and a pharmaceutically acceptable carrier or diluent therefor, wherein the acidifying agent is adapted to reduce the pH at the environment of use to below 4.

12. An animal feed supplement comprising a pharmaceutically acceptable acidifying agent, and a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, in an amount sufficient to produce a beneficial anti-bacterial effect but insufficient to produce an adverse reaction in a target animal.

30 13. An animal feed supplement according to claim 12 wherein the acidifying agent is selected from salicylic or ascorbic acid.

14. An animal feed supplement according to either of claims
35 12 or 13 wherein the source of nitrite ions is an inorganic nitrate.

15. An animal feed supplement according to claim 14 wherein the feed supplement is adapted for the pig, and the inorganic nitrate is present in the feed in an amount sufficient to provide an adult pig with about 1 g/day.

1/4





FIG. 1









FIG. 2 (Continued)





INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 95/00338A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K33/00 A61K47/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 8426 Derwent Publications Ltd., London, GB; AN 84-161228 & JP,A,59 085 278 (AGENCY OF IND. SCI. TECH.), 17 May 1984 see abstract ---	1-3
X	DATABASE WPI Week 8731 Derwent Publications Ltd., London, GB; AN 87-217091 & JP,A,62 142 559 (SHOKO KK) , 25 June 1987 see abstract ---	7,11
A	US,A,4 191 750 (HODOSH) 4 March 1980 -----	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

1

Date of the actual completion of the international search

30 May 1995

Date of mailing of the international search report

16.06.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 95/00338

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4191750	04-03-80	NONE	